[ADVERT]
Share Name Share Symbol Market Type
Ipsen SA EU:IPN Euronext Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.68 0.81% 84.90 84.00 85.00 85.04 83.70 84.50 76,859 16:40:00

Bristol Myers: CHMP Backs Opdivo/Cabometyx in Advanced Renal Cell Carcinoma

26/02/2021 12:27pm

Dow Jones News


Ipsen (EU:IPN)
Historical Stock Chart


From Jan 2021 to Jan 2022

Click Here for more Ipsen Charts.

By Colin Kellaher

 

Bristol Myers Squibb Co. Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of its cancer drug Opdivo in combination with Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma.

The New York biopharmaceutical company said the recommendation is based on a Phase 3 study in which the combination doubled progression-free survival and significantly improved overall survival and response rates.

The European Commission, which generally follows CHMP's advice, will now review the recommendation.

Alameda, Calif., biopharmaceutical company Exelixis Inc. discovered Cabometyx and holds exclusive U.S. rights. French drug maker Ipsen has exclusive rights for the commercialization and further clinical development of the drug outside of the U.S. and Japan under a 2016 deal with Exelixis.

The U.S. Food and Drug Administration in January approved the novel combination of Opdivo and Cabometyx as a first-line treatment of advanced renal cell carcinoma, the most common form of kidney cancer.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

February 26, 2021 07:12 ET (12:12 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Ipsen Chart

1 Year Ipsen Chart

1 Month Ipsen Chart

1 Month Ipsen Chart
ADVFN Advertorial
Your Recent History
EU
IPN
Ipsen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220126 22:59:27